The hemp-derived cannabinoid market continues to grow and evolve despite lingering questions over federal legality and numerous state laws that try to keep pace.

You may have seen or even tried products with a few milligrams of Delta-9 Tetrahydrocannabinol (THC) that were marketed as 2018 Farm Bill-compliant, and if you know anything about the restrictions of the industry; then you’ll know that there are a plethora of laws making THC illegal in multiple states. While delta-9 is the cannabinoid that distinguishes hemp from its federally illegal counterpart, marijuana - companies are still selling Delta-9 products.

So what makes some products ‘compliant’ and some illegal? To begin, we need to go over what exactly Delta-9 is, as well as the difference between cannabis-derived, and hemp-derived THC.

Delta-9 Tetrahydrocannabinol (THC)

THC stands for delta-9-tetrahydrocannabinol or Δ-9-tetrahydrocannabinol (Δ-9-THC). It is a cannabinoid molecule in marijuana (cannabis) that's long been recognized as the main psychoactive ingredient—that is, the substance that causes people who use marijuana to feel high.

Delta-9-THC and Delta-8-THC are the only compounds in the marijuana plant that produce psychoactive effects. Because Delta-9-THC is much more abundant than Delta-8-THC, the psychoactivity of marijuana has been attributed largely to the effects of Delta-9-THC.

The Effects Of Delta-9 THC

The main differentiation between Delta 9 THC and Delta 8 THC is the effects they both provide, which is also the deciding factor for customers. This cannabinoid interacts with the CB1 receptors that are located in the brain, responsible for many processes in the mind such as decision-making, memory, and others.

This powerful compound is said to provide effects such as excitement, euphoria, anxiety, perceptual and visual alterations, restlessness, and others. The effects can be very intense for some users, while others enjoy the outer-worldly experience.

Hemp Vs Cannabis

Although hemp and cannabis look similar, from a functional and chemical perspective, they are distinctive. The term “hemp” is used to describe cannabis that contains 0.3 percent or less THC content per gram on a dry weight basis. Legally, “marijuana” refers to cannabis that has more than 0.3 percent THC by dry weight. THC content can vary among cannabis plants. Some strains are bred to be higher in THC than others.

According to federal law, cannabis—with 0.3% THC content or higher—is classified by the DEA as a Schedule I drug with no accepted medical use. CBD products sourced from cannabis, even those with 0% THC, are illegal at a federal level by virtue of their plant origin. Industrial hemp, on the other hand, is no longer considered a Schedule I controlled drug. Following the 2018 farm bill, hemp was reclassified as an agricultural commodity.

There is no significant difference between hemp delta-9 and regular delta-9, aside from the source. The chemical itself is absolutely identical. The distinction between the delta-9s comes purely from the source, with hemp delta-9 coming from hemp and “regular” delta-9 coming from a standard cannabis plant.

Hemp-Derived THC and the FDA

The 2018 Farm Bill explicitly preserved the authority of the Food and Drug Administration (FDA) to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug and Cosmetic Act. The FDA currently prohibits THC or CBD products from being sold as dietary supplements or as food additives, though the agency is actively investigating whether a pathway should exist for certain CBD ingestible products through the agency’s rulemaking process.

Hemp-Derived THC and State Law

At the state level, the 2018 Farm Bill permits states to implement their own regulatory scheme for the production of hemp so long as the plan is approved by the U.S. Department of Agriculture (USDA).

Is Hemp-Derived Delta-9 Legal?

The confusion surrounding its legality comes from the 2018 Farm Bill, but in a sense there is no cause for confusion at all. The Farm Bill legalizes “hemp” at the federal level, and provides the following definition for hemp:

“The plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.”

Again, state law requires a state-by-state analysis to determine whether a product is legal. There is no “one size fits all” solution and, depending on where a product is sold, there may be labeling, testing and other restrictions to satisfy before a hemp-derived product may be sold legally. To date, states that have enacted state regulations have focused on hemp-derived CBD – not THC or the so-called “novel” cannabinoids such as CBG, CBN and THCA.

Hemp delta-9 is Farm Bill compliant whenever it meets the requirement that it isn’t higher than 0.3% in concentration. Since hemp-derived Delta 9 is legal, you can find it in local dispensaries or even better, online! Like the products that we offer here at Black Tie CBD.

Our Delta-9 products:

Chill Delta 9 THC Microdose Tincture + Terpenes - Pineapple (Indica)

Want to Microdose THC? We have the perfect product for you. Our fast-acting Delta 9 Tinctures contain 5.5 mg of Pure Delta 9 THC plus terpenes in each dose.

420 Mg Delta 9 THC Syrup For Zen - Strawberry (Hybrid)

Looking to find Zen? Find Zen with our Strawberry Hybrid infused Delta 9 Fast Acting Drink Additive/Syrup. This 420 mg bottle comes with approximately 21 servings of 20 mgs per dose. 20 mg Delta 9 THC per serving Fast absorption within as little as 15 minutes.

250 Mg Euphoria Delta 9 THC Gummies - 10 Mg Each (Sativa)

Want to experience5 Euphoria? Our blend of Sativa terpene-infused Delta 9 THC gummies will have you headed to a state of Euphoria! Terpenes include Alpha Pinene and Limonene. Our Delta 9 THC Gummies are 100% Hemp Derived.

‍

The days of an outdated and frankly inaccurate cannabis classification system are finally over. The market has blurred the lines between quality and craft cannabis for far too long - leaving customers and cultivators with no real roadmap to identify the range and spectrum of the medicinal possibilities contained within cannabis and the unique entourage effects possible from the diversity that it offers.

Experts consider Cannabis Indica, Sativa, and Hybrid the three main subspecies - the issue is that people have used the THC potency of strains to determine superiority. Measuring potency and the effects with this method is a long-outdated classification system, especially when it does not provide accurate labels for customers and budtenders alike. The words “Indica” and “Sativa” were introduced in the 18th century to describe different species of cannabis, but modern research has led to more information that we will share throughout this article.

Historically, this is how cannabis has been defined;

Strains

Cannabis Sativa

Sativa is supposedly uplifting and cerebral, enhancing creativity and productivity. Indicas provide what has been called a “body high,” while Sativa’s deliver more of a “mind high.” Unfortunately, Sativa plants require longer to grow and yield less medicine (flowers) than Indica varieties. Sativa’s smell sweet, fruity, or spicy. This difference in the aroma results from terpenes, the molecules within the plant that are cousins to cannabinoids like THC and CBD. While these chemicals sometimes provide stunningly pungent odors, their greatest benefit to patients is their medicinal efficacy.

The problem with the general ‘idea’ of what a Sativa does, is that there is no accurate spectrum representing an understandable visual for growers and customers to understand easily.

Cannabis Indica

The typical example of Cannabis Indica is a more compact, thick-stemmed bush than its cousins, usually reaching a height of fewer than two meters. The foliage is generally a dark shade of green, some examples appearing to have almost blue or green-black leaves. These leaves are composed of short, wide blades.

Most Indicas are supposedly a rich source of the cannabinoids THC, CBD, and CBN. While Cannabis Sativa often produces a higher proportion of THC than its other cannabinoids, Cannabis Indica usually contains significant levels of all three. Indicas tend to have more body-centered effects than Sativas – enhancing physical sensations, which is not accurately measured either.

Cannabis Hybrids

Typically, a Hybrid is a cannabis plant with Indica and Sativa characteristics. Because cannabis has been cultivated for centuries, most modern strains are hybrid. Pure Sativas and pure Indicas are rare, so most cannabis you'll find these days is a hybrid.

Hybrid strains typically develop either Sativa-dominant, Indica-dominant, or evenly balanced phenotypes. Strain descriptions usually list it that way or display the split as a percentage. Remember that the terms Indica and Sativa strains are most useful for cultivators in determining growth characteristics like how tall plants will grow or how long their flowering cycle will be. Effects share no apparent connection with today's cannabis plants' physical structure, hence why the classification system is largely outdated.

So why is this a problem?

According to SC labs (SC Labs is a company that offers comprehensive solutions for cannabis and hemp testing) co-founder, Josh Wurzer;

“The problem is that there is little standardization when it comes to defining and determining terpenes”

Measuring the superiority of cannabis is confusing, and frankly, the classification system is completely outdated. It no longer only comes down to the strain. The days of just searching out the highest THC totals are rapidly receding. Research has proven that terpenes are at the base of the entourage effect, where previously, it has been considered ‘minor’ information. Cannabis growers and breeders have been assigning labels to cultivars primarily based on aroma profiles and purported effects rather than genetic ancestry or overall chemical similarity. Cultivators, processors, retailers, and consumers could benefit from greater standardization when evaluating product quality and distinguishing label claims.

Because cannabis is a widely used substance increasingly being legalized for medicinal and recreational use, Cannabis’s genetic and chemical variation must be accurately quantified and communicated. Using strain labels like Sativa and Indica are used to describe a cultivar’s morphology, aromas and/or psychoactive effects. However, whether these labels capture meaningful information about Cannabis's genetic and chemical variation is incredibly unclear. This leaves room for inaccuracy and uncertainty in a world growing in popularity faster than any other industry.

In this study, the inaccuracy of reporting is clear;

“This is consistent with previous studies indicating that cultivar names were not reliable indicators of a sample’s genetic or chemical identity”

The study shows that the genetic structure of cannabis explained only 37% of the variance in labeling, meaning that Sativa–Indica labels do not accurately reflect genetic relatedness. When the study looked at the correlation of Sativa and Indica terpenes and cannabinoids, Sativa content was positively correlated with the concentrations of bergamotene and farnesene. While on the other hand, there were significant positive correlations between Indica labeling and three sesquiterpenes: guaiol, γ-eudesmol, and β-eudesmol. This shows that it goes far beyond mere classification, and it really comes down to far more than simple labels.

The contrasting aromas that have been associated with Sativa (that is, sweet) and Indica (that is, earthy) were key discriminators in a sensory evaluation of Cannabis cultivars and mediated customers’ perceptions of potency and quality.

What is the solution?

Simple; replace the three vague classes with six elaborate and detailed classifications instead. On February 16th, – SC Laboratories, Inc., (SC Labs) announced that it has licensed Napro Research LLC’s proprietary data visualization tool PhytoFacts®. Clients testing cannabis through the lab will now have access to this game-changing reporting format and algorithm that provides a visual profile of each strain’s chemical makeup. This new report format is intuitive and helps budtenders and consumers identify the right strain for their desired effect. As mentioned above, the terpene profile proves to be far more important than the breed of cannabis, which means that companies like SC Labs are putting an end to the days of simply seeking out the highest THC percentage. Science has converged to finally prove that terpenes are at the root of the entourage effect that consumers are seeking.

Always looking to level their playing field and eliminate as much bias as possible, SC labs' owners partnered with the event organizers of Emerald Cup and NAPRO research to help reframe the conversation regarding what defines “quality” in cannabis. The Emerald Cup is widely believed to be the World Series of Cannabis competitions as it is rooted in Humboldt County. The partnership is intended to help revolutionize the collective understanding of the true role of terpene content.

The new classification system focuses on sorting flower entries by primary terpene content, leveraging a combined decade of research into Cannabis phytochemistry between  PhytoFacts® coupled with a powerful database of over 250,000 terpene tests and aggregated by SC Labs, going back to their launch of terpene testing on Cannabis in 2013 as you can see below.

What are the new classes?

‘Jacks + Haze’ Class

• Mostly ‘Sativa’-leaning varietals
• Tasting notes – Fruity, Pinesol, Haze
• Effects – Energizing, Cerebral, Artistically Inspiring
• Common Cultivars – Classic Trainwreck, Jack Herer, Durban Poison, Super Lemon Haze
• Terpenes Profile: Terpinolene, Caryophyllene, Myrcene

‘Sweets + Dreams’ Class

• Mostly ‘Indica’-leaning varietals
• Tasting Notes – Fruity, Sweet, Woody, Hoppy, Herbaceous
• Effects – Relaxation, Couch Lock, Analgesic
• Common Cultivars – Blue Dream, Tangie, Forbidden Fruit, Grandaddy Purple, Purple Urkel, Grape Ape, Cherry AK, God’s Gift, Purple Punch
• Terpenes Profile: Myrcene, Pinene, Caryophyllene

‘Tropical + Floral’ Class

• Mostly ‘Indica’-leaning varietals
• Tasting notes – Sweet, Floral, Tropical Fruit
• Effects – Calming, Soothing, Relaxing
• Common Cultivars – Super Skunk, Hawaiian, In the Pines, Dream Queen
• Terpenes Profile: Ocimene, Myrcene

‘OGs + Gas’ Class

• True ‘Hybrid’ varietals
• Tasting Notes – Gas, Fuel, Sweet, Citrus, and Pepper
• Effect – Uplifting, Stimulating, Analgesic, Relaxation
• Common Cultivars – Classic OG Kush, Chemdog, Sour Diesel, Gorilla Glue
• Terpenes Profile: Any combination or shifting codominance of Caryophyllene, Limonene, Myrcene

‘Exotics’ (Rare Terpene Combinations) Class

• True ‘Hybrid’ varietals
• Tasting notes – varied based on chemistry of entry
• Effect – varied based on chemistry of entry
• Common Cultivars – rarest terpene profiles entered into the Emerald Cup Competition

‘Desserts’ Class

• True ‘Hybrid’ varietals
• Tasting Notes – Deserts, Doughs, Citrusy & Spicy
• Effects – Stimulating, Racy, Uplifting, Comforting
• Common Cultivars – Classic Bubba Kush, GSC, Gelatos, Cakes
• Any shift in codominance of Caryophyllene & Limonene

How We’re Using The New System

Because of the reliability and shift in the right direction, Black Tie CBD has made use of the latest testing for our ‘ChemDawg’ strain, as you can see below;

As you can see from the report produced by PhytoFacts®, there’s immense detail about the aroma & flavor, identifying the spectrum of profiles in depth. The particular aroma and tastes lean far more towards earthy with some sweet and fruity profiles. Similarly, the entourage effect is highlighted, giving the budtender or end-user a clear idea of its effects. The relaxation and comfort of the strain are highlighted, with lower energy levels. The report is easy to understand and interpret, and above all the classification is distinct without being confusing.

This goes to show how important terpenes really are, and how the entourage effect varies depending on multiple facets which are not usually shown - including highlights of b-Caryophyllene (3.943 mg/g), Myrcene (3.767 mg/g), Terpinolene (2.605 mg/g). The relevance of highlighting terpenes matters significantly because terpenes have also been identified as a new frontier in cannabis medicine. Until recently, the spotlight has been focused almost exclusively on the therapeutic qualities of cannabinoids, such as THC and CBD, but as our understanding of terpenes grows more sophisticated, it’s becoming apparent that these aromatic compounds are medicinal powerhouses too.

β-Caryophyllene: β-Caryophyllene is generally the most common sesquiterpene in cannabis, and the most abundantly produced terpene in Nature. Over the last decade, it has gained scientific attention after discovering that it can directly activate cannabinoids receptors. Basically, the β-Caryophyllene terpene acts as a cannabinoid.

This is the terpene that contributes to the ever-so-slight spicy flavor, but mainly to the earthy profiles as well as the relaxation quality of this strain.

Myrcene: Myrcene is the most abundant terpene in modern commercial cannabis. Myrcene has many therapeutic benefits. Like other terpenes, myrcene is believed to have potential anti-inflammatory, potential anti-tumor, sleep-supportive, and other health benefits.

Myrcene characteristically gives our cannabis strain a mildly sweet flavor profile and provides scent notes that are spicy, earthy and muskiness - and also contributes towards that relaxing and calm effect that was mentioned.

Terpinolene: Terpinolene, a terpene dominant in about one in ten cannabis strains, is recognized for its woody smell combined with floral citrus notes. In addition to its fresh aroma, terpinolene is known for its antifungal and antibacterial properties. Terpinolene is considered more multidimensional in comparison to other cannabis terpenes.

These combined effects and profiles of terpinolene are why there are more fruity aromas and comforting effects. The combination of all three highlighted terpenes should indicate the importance of a more accurate and science-backed classification system to ensure that all effects, aromas and profiles are accounted for.

Without having to handle the substance, users and budtenders can now have a true discourse about the desired flavor, fragrance, and potential effects of cannabis. Consumers may now finally buy cannabis online with ease thanks to the new classification system and PhytoFact® information.

‍

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin.

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries.

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV.

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids.

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain.

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity.

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal?

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV.

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations.

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

‍

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.